Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Savara presented a CHEST 2026 poster with a post-hoc analysis of the Phase 2/3 IMPALA trial showing molgramostim treatment effects in aPAP patients with mild or normal diffusion capacity. In the small subset (8 molgramostim vs. 3 placebo patients), mean A-aDO2 improved by 12.7 mmHg at Week 24 versus 0.3 mmHg on placebo, with reductions in ground-glass opacity and improvements in quality of life.
Key figures
- Drug Name
- molgramostim inhalation solution
- Phase Of Trial
- Phase 2/3
- Trial name
- IMPALA
- Patients analyzed
- 11
- Baseline dlco cutoff
- >70%
- Sgrq t change placebo
- -7.2
- Aado2 change placebo mm Hg
- -0.3
- Sgrq t change molgramostim
- -7.8
- Ggo score change molgramostim
- -4.9
- Aado2 change molgramostim mm Hg
- -12.7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.